Non-Small Cell Lung Cancer

Latest News
October 4th 2024

Nivolumab Approved as Neoadjuvant, Adjuvant Therapy for NSCLC by FDA

September 30th 2024

Amivantamab Presents an Exciting Treatment Opportunity in NSCLC

September 27th 2024

Amivantamab Accolades Add Up for NSCLC

September 26th 2024

FDA Approves Osimertinib in Stage III NSCLC

September 20th 2024

FDA Approves Amivantamab for EGFR-Positive NSCLC With Exon 19 Deletion, Exon 21 L858R Substitution

Video Interviews
View All
September 9th 2024

EMPOWER-Lung 1 Trial Data Showcase Promise of Cemiplimab in NSCLC

September 5th 2024

Dr Ticiana Leal on Recent Advancements in Perioperative NSCLC Care

August 19th 2024

Key Takeaways on Enhancing Outcomes for mNSCLC Without Targetable Driver Mutations

August 12th 2024

Overcoming Immunotherapy Resistance: Identifying Non-Responders and Novel Approaches

August 12th 2024

Clinical Factors Impacting Immunotherapy Response and Optimizing Patient Selection

August 1st 2024

ASCO 2024 and Beyond: Addressing NSCLC Unmet Needs and Future Research Directions

July 24th 2024

Long-Term Follow-Up from CheckMate 9LA at ASCO 2024

July 24th 2024

Insights from the TROPION-Lung05 Trial at ASCO 2024

July 17th 2024

Evaluating Amivantamab and Lazertinib: Key Findings from the CHRYSALIS-2 Study at ASCO 2024

July 17th 2024

ASCO 2024: Key Findings of the LAURA Trial on7:19 Osimertinib for EGFR-Mutated NSCLC

More News

David P. Carbone, MD, PhD, The Ohio State University
September 16th 2024

Liquid Biopsy Advances: Vital Role in Biomarker Testing in Lung Cancer

Maggie L. Shaw
Here we conclude our discussion with David P. Carbone, MD, PhD, The Ohio State University, by addressing the importance of both advocacy for and education on biomarker testing in the lung cancer space.
Sparkling telomere | Image Credit: Dr_Microbe - stock.adobe.com
September 13th 2024

THIO Combo Yields Survival Benefit in Advanced NSCLC

Russ Conroy
Developers anticipate releasing full efficacy results from the phase 2 THIO-101 trial later this year.
Joshua K. Sabari, MD, NYU Langone
August 30th 2024

Novel Mechanisms Set FDA-Approved Amivantamab-Lazertinib Combo Apart in NSCLC

Maggie L. Shaw
This newest approval for amivantamab is the second approval in 6 months for the EGFR and MET bispecific antibody.
Lung cancer | Image credit: Sebastian Kaulitzki - stock.adobe.com
August 27th 2024

Measuring the Magnitude of Systemic Inflammatory Response in NSCLC

Julia Bonavitacola
Measures of systemic inflammation used for the liver, including C-reactive protein-albumin ratio and modified Glasgow prognostic score, demonstrated prognostic value in non–small cell lung cancer (NSCLC).
David P. Carbone, MD, PhD, The Ohio State University
August 23rd 2024

Beyond Early Stage: Biomarker Testing's Role in Advanced Lung Cancer

Maggie L. Shaw
In part 1 of our interview with David P. Carbone, MD, PhD, The Ohio State University, he addressed why it is important to conduct biomarker testing in both lung cancer overall and non–small cell lung cancer more specifically.
FDA Approved
August 20th 2024

Lazertinib With Amivantamab Approved by FDA for Use in NSCLC

Julia Bonavitacola
Patients with non-small cell lung cancer (NSCLC) can use lazertinib in combination with amivantamab as a first-line treatment.
brain and lungs | Image Credit: magicmine-stock.adobe.com
August 15th 2024

ICIs Extend Survival in Older Patients With NSCLC, Brain Metastases

Maggie L. Shaw
This investigation was conducted among older, frail patients, a population typically underrepresented in clinical trials.
Biomarker Testing: Key to Personalized Lung Cancer Care
August 9th 2024

Biomarker Testing: Key to Personalized Lung Cancer Care

Maggie L. Shaw
David P. Carbone, MD, PhD, director of the thoracic oncology center at The Ohio State University in Columbus, discusses the importance of biomarker testing in both lung cancer overall and non–small cell lung cancer specifically.
Lung cancer | Image credit: appledesign - stock.adobe.com
August 5th 2024

Study Suggests Need for New Second-Line NSCLC Therapies to Follow Osimertinib

Julia Bonavitacola
New therapies to treat EGFR-mutated non–small cell lung cancer (NSCLC) following EGFR tyrosine kinase inhibitors (TKIs) are needed to address EGFR TKI resistance after osimertinib.
Lung cancer diagnosis | Image Credit: Vitalii Vodolazskyi-stock.adobe.com
August 1st 2024

NSCLC Study Highlights Need for Adjuvant Trials in Early-Stage Disease

Maggie L. Shaw
Visceral pleural invasion of non–small cell lung cancer (NSCLC) was investigated in this analysis for its potential to predispose patients to worse survival outcomes and greater chances of disease recurrence.
FDA | Image Credit: wladimir1804-stock.adobe.com
July 28th 2024

ODAC Votes to Require Trial Assessment of Neoadjuvant vs Adjuvant Benefits in Resectable NSCLC

Caroline Seymour
Should the FDA require that new trial design proposals for perioperative regimens for resectable non–small cell lung cancer (NSCLC) include adequate within trial assessment?
Lungs | Image credit: yodiyim - stock.adobe.com
July 25th 2024

Atezolizumab for NSCLC Safe and Effective Before and After CRT

Julia Bonavitacola
Patients with unresectable stage III non–small cell lung cancer (NSCLC) who received atezolizumab before and after chemoradiation therapy (CRT) had both safe and effective results.
Antibiotics and lung cancer | Image Credit: Елена Бутусова-stockk.adobe.com
July 19th 2024

NSCLC Care Could Benefit From Antibiotic Stewardship

Maggie L. Shaw
For this analysis, investigators were interested in patient non–small cell lung cancer (NSCLC)–related outcomes from antibiotic administration before immunotherapy alone or immunotherapy and chemotherapy.
Jessica K. Paulus, ScD, Ontada
July 13th 2024

Lung Cancer Detection Trends Show Shift in Pandemic Aftermath

Maggie L. Shaw
In this final segment of our interview with Ontada's Jessica K. Paulus, ScD, she explains how her team's data presented at the American Society of Clinical Oncology annual conference may translate to the real world.
AJMC
July 10th 2024

Patient Satisfaction With Letter-Based Communication of LCS Pulmonary Nodule Results

Daoyue Wang, MD Rui Shi, MD Lili Hu, MD Ran Chen, MD Jun Sun, BS Wei Huang, BS Hongyang Zhou, BS Feng Rong, MD
Patients were satisfied with receiving their lung cancer screening (LCS) pulmonary nodule results via letter and considered the amount of information provided in the letter appropriate.
lung surgery | Image Credit: Tom-stock.adobe.com
July 9th 2024

Age, Pneumonectomy Linked to Poor NSCLC Surgery Outcomes

Maggie L. Shaw
This new analysis incorporated 1997-2013 data on patients with a history of surgical resection of stage IIIA-N2 non-small cell lung cancer (NSCLC) and their postop complications to evaluate the possibility of better identifying future surgical candidates.
Jessica K. Paulus, ScD, Ontada
Published: July 6th 2024 | Updated: July 1st 2024

COVID-19's Potential Impact on Advanced-Stage Lung Cancer Trends

Maggie L. Shaw
In our ongoing interview with Jessica K. Paulus, ScD, Ontada, she explains potential drivers behind changing trends in care for lung cancer that may have been influenced by the COVID-19 pandemic.
Comparative analysis |Image Credit: teguhjatipras-stock.adobe.com
July 3rd 2024

Sotorasib Cost-Effective in US, Not in China for NSCLC

Maggie L. Shaw
Investigators compared cost-effectiveness of the KRAS inhibitor sotorasib against the taxane docetaxel in the second line for non–small cell lung cancer (NSCLC).
essica K. Paulus, ScD, Ontada
June 28th 2024

Real-World Challenges in Cancer Screening: Understanding Data Sources

Maggie L. Shaw
In part 3 of our interview, Jessica K. Paulus, ScD, Ontada, addresses the importance of understanding data sources and their impact on clinical research.
FDA building sign | Image credit: Tada Images – stock.adobe.com
June 27th 2024

FDA Issues CRL for Patritumab Deruxtecan for Locally Advanced, Metastatic EGFR-Mutated NSCLC

Hayden E. Klein
The complete response letter (CRL) was not related to safety or efficacy data, but was a result of inspection findings at a third-party manufacturing facility.
Interview with Jessica K. Paulus, ScD, Ontada
June 22nd 2024

Dr Jessica Paulus: Despite Treatment Advances, Progress in Lung Cancer Will Continue to Take Time

Maggie L. Shaw
“The screening victory there is going to take some more time to show its benefit at the population level,” notes Jessica K. Paulus, ScD. “Some of these things are just going to be reductions in mortality that we have to wait to observe over time.”
image of lung cancer | Image Credit: laszlo-stock.adobe.com
June 21st 2024

Early Detection of PH May Be Key to Improving NSCLC Survival Rates

Maggie L. Shaw
This investigation sought to expand knowledge of the impact of comorbid pulmonary hypertension (PH) on diagnosed non–small cell lung cancer (NSCLC), using data from adult patients treated at military hospital facilities within the US.
Medical Illustration showing lung cancer | Image Credit: Crystallight-stock.adobe.com
June 18th 2024

Second Analysis of FLAURA2 Trial Extends Benefit of Osimertinib Combo in NSCLC

Tony Berberabe, MPH
Encouraging trends were seen with osimertinib and platinum-pemetrexed chemotherapy in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) in the phase 3 FLAURA2 study.
Jessica K. Paulus, ScD, Ontada
June 14th 2024

Ontada’s Dr Jessica Paulus on Investigating Secular Trends in Presenting Lung Cancer Stage

Maggie L. Shaw
This investigation used data from The US Oncology Network on trends in lung cancer stage when patients present for care.
Human lungs with cancer cells| Image Credit: Rasi-stock.adobe.com
June 12th 2024

TRITON Study to Target Biomarkers for Patients With Select NSCLC Mutations

Maggie L. Shaw
The TRITON study is evaluating tremelimumab/durvalumab/chemotherapy vs pembrolizumab/chemotherapy in non–small lung cancer (NSCLC) with STK11 and/or KEAP1 and/or KRAS mutations.
Lung CT | Image Credit: Markoff-stock.adobe.com
June 5th 2024

Broader Studies Needed on Lung Cancer Biopsy Decisions

Maggie L. Shaw
This investigation sprung from a lack of current knowledge on the impact of nonmalignant results following thoracic surgery for lung cancer, according to the authors.
Lung cancer | Image Credit: WrightStudio-stock.adobe.com
May 31st 2024

Awareness and Cost Hinder Lung Cancer Screening for Asian Americans

Maggie L. Shaw
Data presented at the recent American Thoracic Society 2024 international conference identified the top barriers to lung cancer screening in Asian Americans, and common risk factors among this population.
AJMC
May 31st 2024

Physician Preferences for an Electronic Lung Cancer Screening Decision Aid

Orly Morgan, BA Julie B. Schnur, PhD Michael A. Diefenbach, PhD Minal S. Kale, MD, MPH
This qualitative study on primary care physicians yielded suggestions that can inform the design of an effective lung cancer screening decision aid tool and implementation into the electronic health record.
Global currency | Image Credit: Panuwat-stock.adobe.com
May 30th 2024

Durvalumab's High Costs Hinder Global Uptake for Stage III NSCLC Maintenance Therapy

Maggie L. Shaw
This international study, incorporating data from the US, Brazil, Singapore, and Spain, shows that durvalumab as maintenance therapy for use against non–small cell lung cancer remains a cost-prohibitive treatment option.
Lung cancer awareness | Image Credit: WindyNight-stock.adobe.com
May 24th 2024

Body Composition Changes Linked to Poor NSCLC Outcomes

Maggie L. Shaw
For this analysis of how body composition might affect the impact of immunotherapy used to treat non–small cell lung cancer (NSCLC), investigators from Dana-Farber Brigham Cancer Center compared patient outcomes based on baseline body composition measurements or first follow-up scan.
123>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo